Ingevity Q4 net sales down 20% YoY to $298.8M; full-year net loss $430.3M

Ingevity Corp

2024-FY EPS reported -$11.85 revenue$1,406,400,000

Q4 net sales $298.8M (-20% YoY); adjusted EBITDA $80.6M (margin 27.0%); net income $16.6M includes $23.4M restructuring charges.
Full-year net sales $1.4B (-17% YoY); net loss $430.3M on $688M pre-tax charges in Performance Chemicals; adjusted EPS $3.51.
2025 guidance: sales $1.3B-$1.4B, adjusted EBITDA $400M-$415M, free cash flow $220M-$260M.
In January 2025, began exploring strategic alternatives for Performance Chemicals Industrial Specialties line and North Charleston CTO refinery.
Q4 operating cash flow $64.5M included final $50M termination fee payment from a long-term CTO supply agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.